1-month subacute oral toxicity study of KB-944, a new calcium antagonist, in rats.
Diethyl 4-(benzothiazol-2-yl)benzylphosphonate (KB-944), a new Ca-antagonist, in the dose range of 25--200 mg/kg/day, was orally administered to Jcl:SD rats for five consecutive weeks and the following results were obtained. Neither death nor inhibition of body weight gain nor any toxic symptoms of the drug were noted in rats but an increase in water intake was found in the rats treated with over 100 mg/kg/day of KB-944. In plasma there was a decrease in alkaline phosphatase activity, creatinine level and cholinesterase activity and an increase in GPT activity and total cholesterol level in rats given a higher dosage of the drug. Weight gain of the liver, kidneys, heart, adrenals and ovaries, and degeneration in the epithelium of the renal proximal tubule were observed. However, none of these changes were serious and the maximum non-toxic dose of KB-944 was 25 mg/kg/day.
D000818:Animals; D052160:Benzothiazoles; D001769:Blood / Q000187:drug effects; D001772:Blood Cell Count; D001774:Blood Chemical Analysis; D001835:Body Weight / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000633:toxicity*; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D004798:Enzymes / Q000097:blood; D005260:Female; D008297:Male; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D013844:Thiazoles / Q000633:toxicity*; D013997:Time Factors
D052160:Benzothiazoles; D002121:Calcium Channel Blockers; D004798:Enzymes; D013844:Thiazoles; C035950:fosfedil